{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:20:03Z","timestamp":1783938003398,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacasi.2025.11.017","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:25:39Z","timestamp":1769030739000},"page":"748-758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sex Differences in Antiarrhythmic Effects of Empagliflozin"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-2881","authenticated-orcid":false,"given":"Miyo","family":"Nakano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-8456","authenticated-orcid":false,"given":"Shingen","family":"Owada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-7641","authenticated-orcid":false,"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Minamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2025.11.017_bib1","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1253\/circj.CJ-20-1212","article-title":"JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias","volume":"86","author":"Ono","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2025.11.017_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00380-006-0962-9","article-title":"Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus","volume":"22","author":"Movahed","year":"2007","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacasi.2025.11.017_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijcard.2014.08.105","article-title":"Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis","volume":"177","author":"Zaccardi","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/europace\/euab177","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.jacasi.2025.11.017_bib12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12933-024-02309-9","article-title":"Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial","volume":"23","author":"Fujiki","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1164028","article-title":"Sex differences in long QT syndrome","volume":"10","author":"D\u00edez-Escut\u00e9","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"109","key":"10.1016\/j.jacasi.2025.11.017_bib15","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/heartjnl-2022-322243","article-title":"Sex differences in clinical characteristics and prognosis of patients with cardiac sarcoidosis","author":"Iso","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jacasi.2025.11.017_bib16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1152\/ajpheart.00864.2013","article-title":"Sex differences in the mechanisms underlying long QT syndrome","volume":"307","author":"Salama","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacasi.2025.11.017_bib18","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: a systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.jacasi.2025.11.017_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11897-023-00638-6","article-title":"Implications of sex differences on the treatment effectiveness in heart failure with reduced ejection fraction related to clinical endpoints and quality of life","volume":"21","author":"Aydin","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacasi.2025.11.017_bib20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/ehf2.13974","article-title":"Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis","volume":"9","author":"Danielson","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacasi.2025.11.017_bib21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.11.017_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jjcc.2024.02.002","article-title":"Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: a sub-analysis of the PROTECT trial","volume":"84","author":"Kusunose","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jjcc.2024.09.005","article-title":"Impact on ventricular arrhythmic burden of SGLT2 inhibitors in patients with chronic heart failure evaluated with cardiac implantable electronic device monitoring","volume":"85","author":"Basile","year":"2025","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib24","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1161\/CIRCULATIONAHA.105.570648","article-title":"Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease","volume":"113","author":"Kwong","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.11.017_bib25","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jcmg.2016.01.033","article-title":"Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: a meta-analysis","volume":"9","author":"Disertori","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacasi.2025.11.017_bib26","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacasi.2025.11.017_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacasi.2025.11.017_bib28","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.11.017_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/eurheartj\/ehv598","article-title":"Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes","volume":"37","author":"Regitz-Zagrosek","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.11.017_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacasi.2025.11.017_bib31","first-page":"707","article-title":"Ovarian follicle atresia: a hormonally controlled apoptotic process","volume":"15","author":"Hsueh","year":"1994","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jacasi.2025.11.017_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.11.017_bib33","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.122.062832","article-title":"Sex differences in characteristics, outcomes, and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: Insights from DAPA-HF and DELIVER","volume":"147","author":"Wang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.11.017_bib34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.11.017_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jacasi.2025.11.017_bib36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacasi.2025.11.017_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of atrial arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00021.2015","article-title":"Mechanistic pathways of sex differences in cardiovascular disease","volume":"97","author":"Regitz-Zagrosek","year":"2017","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jacasi.2025.11.017_bib39","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"Sabolic","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib40","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacasi.2025.11.017_bib41","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.11.017_bib42","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.5551\/jat.48009","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume and P-wave indices: An ad-hoc analysis of the previous randomized clinical trial","volume":"27","author":"Sato","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacasi.2025.11.017_bib43","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.3390\/cimb46090571","article-title":"Recent advances in understanding the molecular mechanisms of SGLT2 inhibitors in atrial remodeling","volume":"46","author":"Minciun\u0103","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib44","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","article-title":"Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacasi.2025.11.017_bib45","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bcp.12056","article-title":"The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus","volume":"76","author":"Kasichayanula","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib46","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacasi.2025.11.017_bib47","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1093\/eurheartj\/ehw331","article-title":"Regional and ethnic differences among patients with heart failure in Asia: the ASIAN-HF registry","volume":"37","author":"Lam","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.11.017_bib48","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2015.12.011","article-title":"Sudden cardiac death in Asia and China: Are we different?","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.11.017_bib49","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.109.914820","article-title":"Pharmacogenomics: the genetics of variable drug responses","volume":"123","author":"Roden","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.11.017_bib50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4093\/dmj.2022.0002","article-title":"Real-world prescription patterns and barriers related to the use of sodium-glucose cotransporter 2 inhibitors among korean patients with type 2 diabetes mellitus and cardiovascular disease","volume":"46","author":"Baek","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jacasi.2025.11.017_bib51","first-page":"101539","article-title":"Representation of women and racial minorities in SGLT2 inhibitors and heart failure clinical trials","volume":"55","author":"Gupta","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jacasi.2025.11.017_bib52","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.hrthm.2011.12.013","article-title":"Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial","volume":"9","author":"Cheng","year":"2012","journal-title":"Heart Rhythm"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374725007033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374725007033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:42:49Z","timestamp":1778010169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374725007033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2772374725007033"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.11.017","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex Differences in Antiarrhythmic Effects of Empagliflozin","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}